Vigil Neuroscience, Inc., (VIGL): Price and Financial Metrics
VIGL Price/Volume Stats
| Current price | $2.82 | 52-week high | $11.11 |
| Prev. close | $2.75 | 52-week low | $2.53 |
| Day low | $2.58 | Volume | 64,624 |
| Day high | $2.96 | Avg. volume | 100,408 |
| 50-day MA | $3.15 | Dividend yield | N/A |
| 200-day MA | $4.89 | Market Cap | 104.02M |
VIGL Stock Price Chart Interactive Chart >
Vigil Neuroscience, Inc., (VIGL) Company Bio
Vigil Neuroscience, Inc., a biotechnology company, discovers and develops novel therapeutics that take advantage of breakthroughs in science and human genetics of microglia. It harnesses the power of microglia for the treatment of neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.
Latest VIGL News From Around the Web
Below are the latest news stories about VIGIL NEUROSCIENCE INC that investors may wish to consider to help them evaluate VIGL as an investment opportunity.
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx ConferenceWATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, at 3:50 p.m. |
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent with Phase 1 data; Directionally supportive changes in individual patients at 6 months on MRI and NfL biomarkers - - Natural History Study continued to provide critical insights on MRI and NfL biomarkers; sCSF1R emerging as key biomarker of ALSP disease pathology - - Company expects to report Phase 2 I |
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small molecule TREM2 agonist in clinical development for potential treatment of Alzheimer’s disease – – Announced VGL101 complete Phase 1 data analysis and Phase 2 IGNITE trial design at 2023 ANA Annual Meeting – WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a cli |
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s DiseaseWATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company has dosed its first participant in a Phase 1 clinical trial in healthy volunteers evaluating VG-3927, the first and only small molecule TREM2 agonist in the clinic for the potential treatment of Alzheimer’s disease (AD). “Dosing the first |
Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
VIGL Price Returns
| 1-mo | -12.15% |
| 3-mo | -1.40% |
| 6-mo | -61.94% |
| 1-year | -71.17% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -16.57% |
| 2023 | -72.96% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...